tPA drug, COVID-19, anti-clotting drug, COVID-19 Treatment, Health IT Industry, healthcare services, COVID-19 pandemic

There Might be a Breakthrough for COVID-19 Respiratory Failure Cure

COVID-19 has struck everything. From people to the economy, everything is suffering, and the death toll is increasing day by day. While some countries have managed to restrict the risk like China, some are still struggling.

The symptoms of this infection are cough, flu, fever, and fatal respiratory issues. Although, this virus is serious but not every COVID positive person ends up in the hospital, generally, the intense or worse cases require hospitalization. As a result of acute respiratory distress syndrome (ARDS), which is a severe lung injury, these patients seek serious medical assistance.

A concrete cure for ARDS is still not found. Physicians treat the bearer of this disease with mechanical ventilation and supportive care.

What Health IT Industry is doing for COVID-19 Treatment?

A team of physician-scientists is conducting research and testing out the anti-clotting drug for serious COVID infectees with ARDS. After several tests and trials, the scientists have concluded that a drug called tPA has the potential to reduce the death rate among ARDS infectees.

Researchers say that this drug can be life-changing. It can reduce recovery time and with a faster recovery time of patients, there can be more ventilators available.

A Little History

The US Food and Drug Administration in 1996 approved tPA to be used for patients experiencing a heart attack, stroke, and pulmonary embolism.

Therefore, for two decades, researchers have found anti-clotting drugs useful against ADRS diseases.

FDA really didn’t give thumbs up to this method. However, for ARDS induced COVID patients, this drug might work.

How An Anti-Clotting Drug is Expected to Help COVID?

There is major clotting around IV lines in many COVID patients. Researchers are hopeful that tPA drug can show fruitful results in severe patients or at least tell if the assumption is true.

This clinical trial committee is now enrolling patients.

Later on, they will record biomarkers, such as, the medical conditions of each patient to identify under which conditions tPA gives the most advantage. The drug is already approved on a large scale to treat heart patients and people with strokes as an off-label medicine.

The COVID Effect on American Hospitalization Capability

This pandemic is not over. We don’t have any effective treatment for it at the moment, and the number of COVID-19 infected persons is only going to rise.

When the lockdown will lift up, chances are the pandemic situation will get worse. According to a study, many more Americans are expected to use ventilation services in the upcoming months. Looking into statistics, America has currently 200,000 ventilators.

With collective efforts, hopefully, we’ll be able to generate an effective strategy to deal and restrict COVID -19.

Before the pressure of pandemic saturates our healthcare services, it is important to consider the existing therapies and procedures that may help us to accommodate the surge of patients in the future. These procedures/therapies must be widely available so that they serve the purpose of easily accessible healthcare to COVID.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *